Bullish indicating open at $55-$60, IPO prices at $37
Investing.com - BMO Capital has lowered its price target on AMN Healthcare (NYSE:AMN) to $22.00 from $27.00 while maintaining an Outperform rating on the healthcare staffing company. The stock has declined over 70% in the past year, though InvestingPro analysis suggests the company is currently undervalued based on its Fair Value assessment.
The price target reduction follows AMN Healthcare’s second-quarter 2025 earnings results, which exceeded consensus estimates primarily due to stronger margins despite softer volumes.
BMO Capital noted that recent government policies and macroeconomic volatility have negatively impacted healthcare staffing volumes, with Academic Medical (TASE:BLWV) Centers that rely on federal funding experiencing the most significant declines.
The research firm reported some stabilization in July, but AMN’s third-quarter 2025 revenue guidance came in below consensus expectations due to the volume decreases.
BMO Capital acknowledged that AMN Healthcare’s stock could face pressure due to lower volumes, though it suggested that some of this negative impact may already be reflected in the current share price.
In other recent news, AMN Healthcare Services Inc reported a notable earnings beat for the second quarter of 2025. The company announced earnings per share (EPS) of $0.30, significantly exceeding the forecasted $0.18. Additionally, AMN Healthcare’s revenue surpassed expectations, reaching $658.18 million compared to the projected $652.63 million. These results highlight the company’s stronger-than-anticipated financial performance. Despite the positive earnings and revenue figures, the company’s stock experienced a decline, reflecting broader market uncertainties and concerns over a net loss. Analyst firms have not issued any recent upgrades or downgrades for AMN Healthcare. Investors continue to monitor these developments closely as they assess the company’s financial health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.